Entellus Medical

2015 News Releases

Keyword Search
 
2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
08/25/15Entellus Medical Surpasses 100,000 Patients Treated Worldwide
XprESS(TM) Balloon Sinus Dilation Systems the Most Widely Used in ENT Offices PLYMOUTH, Minn., Aug. 25, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today announced that it estimates that over 100,000 patients worldwide have been treated using its XprESS Multi-Sinus Dilation System since the launch ... 
08/10/15Entellus Medical Announces Exclusive Collaboration With Fiagon
Fiagon Image Guidance Technology Complements Entellus Medical's Portfolio of Products for the Treatment of Chronic Sinusitis in ENT Offices and Ambulatory Surgery Centers PLYMOUTH, Minn., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. ("Entellus Medical" or the "Company") (NASDAQ:ENTL), a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician offic... 
08/06/15Entellus Medical Announces Second Quarter 2015 Financial Results
PLYMOUTH, Minn., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. ("Entellus Medical" or the "Company") (NASDAQ:ENTL), a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today reported its financial results for the quarter ended June 30, 2015. Recent Highlights and Accomplishments Revenues of $15.2 m... 
07/31/15Entellus Medical Announces Positive 24 Month Data From Remodel Trial and Meta-Analysis Across 6 Studies
Long-term follow-up results consistent with previously reported 6-month and 12-month outcomes Larger cohort of patients affirmed benefits of balloon sinus dilation reported in earlier publications Meta-analysis of 358 patients across 6 studies confirms benefits of balloon sinus dilation PLYMOUTH, Minn., July 31, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent ... 
07/28/15Entellus Medical to Present at Upcoming Investor Conferences
PLYMOUTH, Minn., July 28, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today announced the Company will be participating in two upcoming investor conferences. Entellus Medical's management is scheduled to present at the Wedbush PacGrow Healthcare Conference in New York City, NY on Tuesday, August... 
07/23/15Entellus Medical to Report Second Quarter 2015 Financial Results on August 6, 2015
Conference Call Scheduled for Thursday, August 6, 2015 at 4:30pm ET PLYMOUTH, Minn., July 23, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today announced that it will release its financial results for the second quarter of 2015 after the close of trading on Thursday, August 6, 2015. The Company's m... 
07/09/15Entellus Medical Appoints John Bakewell to Its Board of Directors
PLYMOUTH, Minn., July 9, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company focused on designing, developing and commercializing products for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced that John Bakewell, Chief Financial Officer of Lantheus Holdings, Inc. (NASDAQ:LNTH), has been appointed to its Board of Directors and will be serving on the audit committee, effective July 7, 2015. Mr. Bakewell is an a... 
07/07/15Entellus Medical Expands Capacity to Accommodate Growth
PLYMOUTH, Minn., July 7, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company focused on designing, developing and commercializing products for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced that it has entered into a lease agreement for approximately 19,700 additional square feet to its existing premises in Plymouth, MN. The Company is expected to be in possession of the additional space beginning in February ... 
06/01/15Entellus Medical Announces European Launch of XprESS(TM) LoProfile Multi-Sinus Dilation System
Company to Showcase XprESS LoProfile at the Congress of European ORL-HNS PLYMOUTH, Minn., June 1, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company focused on designing, developing and commercializing products for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced the European launch of the XprESS™ LoProfile Multi-Sinus Dilation System. The XprESS LoProfile product is used by ENT (Ear, Nose and Throat) physicia... 
05/26/15Entellus Medical to Present at William Blair 35th Annual Growth Stock Conference
PLYMOUTH, Minn., May 26, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today announced the company plans to participate in the William Blair 35th Annual Growth Stock Conference in Chicago, IL. Entellus Medical's management is scheduled to present on Wednesday, June 10, 2015 at 4:40pm CT. Intereste... 
05/07/15Entellus Medical Announces First Quarter 2015 Financial Results
Updates 2015 Financial Outlook PLYMOUTH, Minn., May 7, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. ("Entellus Medical" or the "Company") (Nasdaq:ENTL), a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today reported its financial results for the three months ended March 31, 2015. Recent Highlights and Accompl... 
04/30/15Entellus Medical to Present at Bank of America Merrill Lynch 2015 Health Care Conference
PLYMOUTH, Minn., April 30, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today announced the company plans to participate in the Bank of America Merrill Lynch 2015 Health Care Conference in Las Vegas, NV. Entellus Medical's management is scheduled to present on Thursday, May 14, 2015 at 12:40pm PT... 
04/23/15Entellus Medical to Report First Quarter 2015 Financial Results on May 7, 2015
Conference Call Scheduled for Thursday, May 7, 2015 at 4:30pm ET PLYMOUTH, Minn., April 23, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today announced that it will release its financial results for the first quarter of 2015 after the close of trading on Thursday, May 7, 2015. The Company's managem... 
04/02/15Entellus Medical Announces Promotion of Robert White to Chief Executive Officer, and Preliminary First Quarter 2015 Revenues of $13.4 to $13.5 Million
PLYMOUTH, Minn., April 2, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. ("Entellus Medical" or the "Company") (Nasdaq:ENTL), a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, announced that effective today, Robert White, President and Chief Operating Officer of the Company has been promoted to President and Chief Exe... 
03/17/15Entellus Medical Announces Fourth Quarter and Full Year 2014 Financial Results and Provides 2015 Financial Outlook
PLYMOUTH, Minn., March 17, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. ("Entellus Medical" or the "Company") (Nasdaq:ENTL), a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today reported its financial results for the three months and year ended December 31, 2014. Recent Highlights and Accomplishments ... 
03/03/15Entellus Medical to Report Fourth Quarter and Full Year 2014 Financial Results on March 17, 2015
Conference Call Scheduled for Tuesday, March 17, 2015 at 4:30pm ET PLYMOUTH, Minn., March 3, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today announced that it will release its financial results for the fourth quarter and full year of 2014 after the close of trading on Tuesday, March 17, 2015. The... 
02/13/15Entellus Medical Announces Release of XprESS(TM) Ultra Multi-Sinus Dilation System
PLYMOUTH, Minn., Feb. 13, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today announced the release of the XprESS™ Ultra Multi-Sinus Dilation System, the third device in the XprESS family of balloon sinus dilation systems. XprESS Ultra provides the precision, versatility and control of the XprESS ... 
02/03/15Entellus Medical, Inc. Announces Closing of Initial Public Offering
PLYMOUTH, Minn., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, announced today the closing of its initial public offering of 5,294,117 shares of its common stock (including 690,537 shares purchased by the underwriters pursuant to an option to purchase additional shares) at a public offering pr... 
01/28/15Entellus Medical, Inc. Announces Pricing of Initial Public Offering
PLYMOUTH, Minn., Jan. 28, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc., a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, announced today the pricing of its initial public offering of 4,603,580 shares of its common stock at an initial public offering price of $17.00 per share, before underwriting discounts and commissions. The shares are expected to begin trading ...